AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29178711 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste plus 3% KNO3 mouthwash
Number of subjects: 216
Study 29178711 — intervention group
Group type: COMPARATOR
Intervention: Fluoride toothpaste alone
Number of subjects: 216
Study 26547062 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-messaging smoking cessation intervention
Number of subjects: 197
Study 26547062 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 197
Study 25100444 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal moves (full video clips)
Number of subjects: 0
Study 25100444 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceptive moves
Number of subjects: 0
Study 25100444 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-light clips (normal turns)
Number of subjects: 0
Study 25100444 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-light clips (deceptive turns)
Number of subjects: 0
Study 21929528 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO (800 IU/kg intravenously)
Number of subjects: 50
Study 21929528 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 50
Study 19429518 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective strapping of the rib cage
Number of subjects: 10
Study 19429518 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective strapping of the abdomen
Number of subjects: 10
Study 19429518 — intervention group
Group type: EXPERIMENTAL
Intervention: Total chest wall strapping
Number of subjects: 10
Study 19429518 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (no strapping)
Number of subjects: 10
Study 17235334 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 8 mg/day for 6 months
Number of subjects: 37
Study 17235334 — intervention group
Group type: COMPARATOR
Intervention: placebo for 6 months
Number of subjects: 37
Study 14768919 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (1 microg kg(‐1) bolus then 0.1‐0.5 microg kg(‐1) min‐1)
Number of subjects: 98
Study 14768919 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (30 microg kg(‐1) bolus then 0.16‐0.83 microg kg(‐1) min‐1)
Number of subjects: 98
Study 14768919 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 98
Study 14768919 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 98
Study 14768919 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 98
Study 12480424 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin (20 mg/kg bodyweight, maximum individual dose 1 g; n=65)
Number of subjects: 128
Study 12480424 — intervention group
Group type: COMPARATOR
Intervention: 12.5 mg/kg erythromycin (maximum dose 500 mg; n=63)
Number of subjects: 128
Study 9620115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of a standard trivalent influenza vaccine
Number of subjects: 26
Study 9620115 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of a standard trivalent influenza vaccine
Number of subjects: 26
Study 8590521 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal dilatation
Number of subjects: 0
Study 8590521 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors
Number of subjects: 0
Study 8590521 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic dilatation
Number of subjects: 0
Study 8590521 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 0
Study 8590521 — intervention group
Group type: COMPARATOR
Intervention: Blind passage, fluoroscopic guidance, endoscopically directed dilatation
Number of subjects: 0
Study 2295775 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk/jog (n = 17)
Number of subjects: 49
Study 2295775 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (n = 20)
Number of subjects: 49
Study 2295775 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 49
Study 347112 — intervention group
Group type: EXPERIMENTAL
Intervention: deanol acetamidobenzoate, 2.0 g/day for four weeks
Number of subjects: 14
Study 347112 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 30367462 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0
Study 30367462 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0
Study 30367462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28069021 — intervention group
Group type: EXPERIMENTAL
Intervention: EXPECT (psychological pre-surgery intervention to optimize outcome expectations)
Number of subjects: 124
Study 28069021 — intervention group
Group type: COMPARATOR
Intervention: SUPPORT (psychological control intervention focusing on emotional support)
Number of subjects: 124
Study 28069021 — intervention group
Group type: COMPARATOR
Intervention: SMC (standard medical care)
Number of subjects: 124
Study 28069021 — intervention group
Group type: EXPERIMENTAL
Intervention: EXPECT
Number of subjects: 124
Study 28069021 — intervention group
Group type: EXPERIMENTAL
Intervention: EXPECT and SUPPORT
Number of subjects: 124
Study 25932600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 112
Study 25932600 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 112
Study 23460409 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT) size 2
Number of subjects: 40
Study 23460409 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Mask Airway (LMA) size 2
Number of subjects: 40
Study 21711059 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg twice daily
Number of subjects: 875
Study 21711059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 875
Study 19139013 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 13‐cis‐retinoic acid daily, alpha‐IFN twice weekly, and alpha‐tocopherol daily for 1 year
Number of subjects: 27
Study 19139013 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance fenretinide
Number of subjects: 27
Study 19139013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 19139013 — intervention group
Group type: EXPERIMENTAL
Intervention: CD1 AA/AG genotype
Number of subjects: 27
Study 19139013 — intervention group
Group type: EXPERIMENTAL
Intervention: High CD1 expression
Number of subjects: 27
Study 17337141 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg
Number of subjects: 121
Study 17337141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 15325237 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural compounds collected from lactating women and their breastfeeding infants
Number of subjects: 0
Study 11397028 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ultrasonic scan at age 65
Number of subjects: 6058
Study 11397028 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group (including refusers)
Number of subjects: 6058
Study 11397028 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group
Number of subjects: 6058
Study 11397028 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled sample offered a scan at age 65
Number of subjects: 6058
Study 11397028 — intervention group
Group type: EXPERIMENTAL
Intervention: Initially normal aortic diameter
Number of subjects: 6058
Study 9425670 — intervention group
Group type: EXPERIMENTAL
Intervention: Single judgment task for spatial frequency or contrast
Number of subjects: 0
Study 9425670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual discrimination of contrast and spatial frequency
Number of subjects: 0
Study 9425670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual discrimination of 2 contrast or spatial frequency components
Number of subjects: 0
Study 9425670 — intervention group
Group type: COMPARATOR
Intervention: Relative spatial location of components
Number of subjects: 0
Study 8438775 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg/d)
Number of subjects: 45
Study 8438775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 3098825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular route of FSH administration
Number of subjects: 12
Study 3098825 — intervention group
Group type: COMPARATOR
Intervention: Pulsatile subcutaneous route of FSH administration
Number of subjects: 12
Study 29189279 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine (group AL)
Number of subjects: 213
Study 29189279 — intervention group
Group type: COMPARATOR
Intervention: Saline (group S)
Number of subjects: 213
Study 26540368 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 115
Study 26540368 — intervention group
Group type: COMPARATOR
Intervention: No patellar resurfacing (Control)
Number of subjects: 115
Study 25329386 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational small groups meetings led by pharmacists (TEA trial)
Number of subjects: 1737
Study 25329386 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational small groups meetings led by pharmacists (SIDRO trial)
Number of subjects: 1737
Study 23558840 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (IV 8 mg)
Number of subjects: 185
Study 23558840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 20615884 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled HPV genotype test (hybrid capture 2; hc2)
Number of subjects: 671
Study 20615884 — intervention group
Group type: COMPARATOR
Intervention: Research PCR HPV genotyping test (line blot assay; LBA)
Number of subjects: 671
Study 20615884 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent HPV16 among women repeatedly hc2+
Number of subjects: 671
Study 18793930 — intervention group
Group type: EXPERIMENTAL
Intervention: F-file
Number of subjects: 60
Study 18793930 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonically activated #20 K-file
Number of subjects: 60
Study 18793930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically activated #20 K-file with EDTA
Number of subjects: 60
Study 18793930 — intervention group
Group type: EXPERIMENTAL
Intervention: F-file with EDTA
Number of subjects: 60
Study 12114338 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg once daily via dry-powder inhaler
Number of subjects: 623
Study 12114338 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg bid via metered-dose inhaler
Number of subjects: 623
Study 12114338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 623
Study 9424040 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 419
Study 9424040 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 419
Study 9424040 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention (for those with 3 or fewer well-child visits)
Number of subjects: 419
Study 9424040 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention (for the 25% with inadequate preventive health visits)
Number of subjects: 419
Study 8586119 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 ppm NO2 for 20 min (Group A)
Number of subjects: 24
Study 8586119 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 ppm NO2 for 20 min (Group B)
Number of subjects: 24
Study 8586119 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 ppm NO2 for 4 h (Group C)
Number of subjects: 24
Study 2671369 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education programme on salt reduction
Number of subjects: 800
Study 2671369 — intervention group
Group type: COMPARATOR
Intervention: Control community (no intervention)
Number of subjects: 800
Study 782144 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (Inderal) 160 mg/d
Number of subjects: 22
Study 782144 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (Inderal)
Number of subjects: 22
Study 31512187 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring with team-based management
Number of subjects: 240
Study 31512187 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study 31037755 — intervention group
Group type: EXPERIMENTAL
Intervention: six-session face-to-face individual intervention
Number of subjects: 154
Study 31037755 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 154
Study 28034981 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (IVA) 1000 mg
Number of subjects: 67
Study 28034981 — intervention group
Group type: COMPARATOR
Intervention: Oral acetaminophen (OA) 1000 mg
Number of subjects: 67
Study 28034981 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IVA and OA
Number of subjects: 67
Study 26426451 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention modification (AMC)
Number of subjects: 68
Study 26426451 — intervention group
Group type: EXPERIMENTAL
Intervention: Attend-to-geometrics (AGC)
Number of subjects: 68
Study 26426451 — intervention group
Group type: COMPARATOR
Intervention: Attention control (ACC)
Number of subjects: 68
Study 26426451 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 68
Study 22883130 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulative therapy (SMT)
Number of subjects: 69
Study 22883130 — intervention group
Group type: COMPARATOR
Intervention: Sham-SMT
Number of subjects: 69
Study 22883130 — intervention group
Group type: COMPARATOR
Intervention: Sham-ultrasound
Number of subjects: 69
Study 22286593 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative psychotherapeutic programme (IRR)
Number of subjects: 168
Study 22286593 — intervention group
Group type: COMPARATOR
Intervention: Usual nursing home care
Number of subjects: 168
Study 18719060 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative smoking cessation intervention (PISC)
Number of subjects: 0
Study 18719060 — intervention group
Group type: COMPARATOR
Intervention: Control group (not subjected to PISC)
Number of subjects: 0
Study 17113139 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-step etch-and-rinse adhesive systems (Allbond 2, Clearfil LB, Denthesive)
Number of subjects: 337
Study 17113139 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step etch-and-rinse adhesive system (Gluma 2000)
Number of subjects: 337
Study 17113139 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch adhesive systems (ART, Denthesive 2, PUB 3)
Number of subjects: 337
Study 17113139 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall retention of all adhesive systems
Number of subjects: 337
Study 17113139 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA acceptance criteria
Number of subjects: 337
Study 16871741 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis with glucose-containing fluid
Number of subjects: 123
Study 16871741 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis with glucose-free fluid
Number of subjects: 123
Study 16871741 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study 11313230 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education campaigns in target villages
Number of subjects: 577
Study 11313230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education campaign)
Number of subjects: 577
Study 9387175 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 burns to half of the trabecular meshwork
Number of subjects: 122
Study 9387175 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 burns to one third of the trabecular meshwork
Number of subjects: 122
Study 8197033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg every 12 hours (C500)
Number of subjects: 24
Study 8197033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg every 12 hours (C750)
Number of subjects: 24
Study 8197033 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalidixic acid 1 g every 6 hours (NA)
Number of subjects: 24
Study 8197033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2884813 — intervention group
Group type: EXPERIMENTAL
Intervention: guanfacine 1-2 mg
Number of subjects: 13
Study 2884813 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study 31202690 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir 400 mg once daily
Number of subjects: 300
Study 31202690 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted lopinavir 800 mg plus 200 mg ritonavir
Number of subjects: 300
Study 27883220 — intervention group
Group type: EXPERIMENTAL
Intervention: Zingiber officinale-based lip plumper
Number of subjects: 60
Study 24928790 — intervention group
Group type: EXPERIMENTAL
Intervention: FP‐01.1 (150 μg/peptide dose group)
Number of subjects: 49
Study 24928790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 23705536 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily patient-applied subgingival root brushing for 14 days
Number of subjects: 11
Study 23705536 — intervention group
Group type: COMPARATOR
Intervention: Pre-existing tooth brushing and flossing regimen (Control)
Number of subjects: 11
Study 22256633 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion treatment (3 cones on each point, applied to Neixiyan, Dubi, and Ashi points, once every two days, 3 times per week for 6 weeks)
Number of subjects: 59
Study 22256633 — intervention group
Group type: COMPARATOR
Intervention: Placebo moxibustion treatment (placebo moxa sticker applied to the same points)
Number of subjects: 59
Study 19822595 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cysteine (81 mg/kg per day)
Number of subjects: 20
Study 19822595 — intervention group
Group type: COMPARATOR
Intervention: Standard dose cysteine (45 mg/kg per day)
Number of subjects: 20
Study 16477445 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of supervised sprint training program (3 days/week)
Number of subjects: 12
Study 16477445 — intervention group
Group type: COMPARATOR
Intervention: Normal activity (control group)
Number of subjects: 12
Study 15243608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower stabilising splint (SS)
Number of subjects: 93
Study 15243608 — intervention group
Group type: COMPARATOR
Intervention: Non-occluding control (CS)
Number of subjects: 93
Study 11552140 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin adhesive
Number of subjects: 26
Study 11552140 — intervention group
Group type: COMPARATOR
Intervention: Resorbable oxycellulose dressing
Number of subjects: 26
Study 9644774 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sequential regimen of 5 micrograms/day of estradiol and 5 mg/day of medrogestone from the 17th to the 28th day of the cycle (Group A)
Number of subjects: 80
Study 9644774 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of 50 micrograms/day estradiol and 5 mg/day medrogestone (Group B)
Number of subjects: 80
Study 8187428 — intervention group
Group type: EXPERIMENTAL
Intervention: 40, 80, 120, 160 or 200 mg rimexolone (Org 6216)
Number of subjects: 20
Study 3556307 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation therapy
Number of subjects: 124
Study 3556307 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemo‐irradiation therapy (Adriamycin/Cyclophosphamide)
Number of subjects: 124
Study 3556307 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined irradiation-polychemotherapy (Adriamycin/Cyclophosphamide or Adriamycin/Cisplatin)
Number of subjects: 124
Study 3556307 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 124
Study 3556307 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined polychemotherapy including Cisplatin
Number of subjects: 124
Study 3556307 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 124
Study 3556307 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage I tumors
Number of subjects: 124
Study 3556307 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II tumors
Number of subjects: 124
Study 29205286 — intervention group
Group type: EXPERIMENTAL
Intervention: Anamorelin (100 mg daily for 12 weeks)
Number of subjects: 174
Study 29205286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 27127006 — intervention group
Group type: EXPERIMENTAL
Intervention: Avastin (bevacizumab) in combination with Temozolomide (TMZ) and Radiotherapy
Number of subjects: 121
Study 27127006 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional MR imaging plus diffusion/perfusion imaging
Number of subjects: 121
Study 27127006 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging
Number of subjects: 121
Study 24942094 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric ultrasonic bone surgery system
Number of subjects: 60
Study 24942094 — intervention group
Group type: COMPARATOR
Intervention: Traditional bone chisels method
Number of subjects: 60
Study 23647914 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration training (3 sessions per week, 5 series of 15 seconds at 30 Hz frequency)
Number of subjects: 62
Study 23647914 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal daily life)
Number of subjects: 62
Study 20089253 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated chronic care program (ICCP)
Number of subjects: 698
Study 18470902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine alone
Number of subjects: 197
Study 18470902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine and cyclophosphamide combination
Number of subjects: 197
Study 18470902 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, vincristine, and prednisone combination
Number of subjects: 197
Study 18470902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine-containing regimens (both cladribine alone and cladribine and cyclophosphamide combination)
Number of subjects: 197
Study 18470902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine alone and cladribine and cyclophosphamide combination
Number of subjects: 197
Study 18470902 — intervention group
Group type: COMPARATOR
Intervention: Cladribine alone, cladribine and cyclophosphamide combination, and cyclophosphamide, vincristine, and prednisone combination
Number of subjects: 197